Search
for
Sort by
Research 811–840 of 1000+
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- Evaluation of Effectiveness of Bio-Micro Injection in Treating Alopecia Universalis: A Non-Randomized Interventional Study
- A clinical case of familial alopecia areata in combination with immune pathology
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
- Abstracts from the 2024 WDS Forum - virtual option
- Title Choice of treatment for severe forms of alopecia areata (case reports)
- Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- Successful treatment of resistant alopecia totalis with tofacitinib
- Editorial: Targeted immunological therapies in dermatology
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Alopecia areata: Time for position statement to include new systemic therapeutic advances
- A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report
- Advances in the mechanism and new therapies of alopecia areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Meeting Report: 68th Montagna Symposium on the Biology of Skin “Decoding Complex Skin Diseases: Integrating Genetics, Genomics, and Disease Biology”
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- New Drugs for Alopecias
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials